

# Investment case for eliminating mother-to-child transmission of syphilis

Promoting better  
maternal and child health  
and stronger health systems



World Health  
Organization

initiative for the global elimination of congenital syphilis



# Investment case for eliminating mother-to-child transmission of syphilis

Promoting better maternal and child health and stronger health systems



#### WHO Library Cataloguing-in-Publication Data

Investment case for eliminating mother-to-child transmission of syphilis: promoting better maternal and child health and stronger health systems.

1.Syphilis – transmission. 2.Syphilis – prevention and control. 3.Syphilis, Congenital. 4.Infectious Disease Transmission, Vertical. 5.Infant, Newborn, Diseases. I.World Health Organization.

ISBN 978 92 4 150434 8

(NLM classification: WC 161)

© **World Health Organization 2012**

All rights reserved. Publications of the World Health Organization are available on the WHO web site ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site ([http://www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland

# Contents

Acknowledgements	v
Abbreviations and acronyms	vi
Executive summary	1
1. The case for investment	2
1.1 Mother-to-child transmission of syphilis: a continuing public health burden	2
1.2 Addressing syphilis in pregnant women: a feasible solution	3
1.3 Why now is the time to invest in elimination of mother-to-child transmission of syphilis	3
1.4 Why the problem persists	5
1.5 The strong economic case for syphilis elimination	6
1.6 Who should invest in the elimination of mother-to-child transmission of syphilis?	8
1.7 How much and what sort of investment is needed?	9
2. Details of the initiative: objectives, activities and stakeholders	10
2.1 Choosing 10 intensified support countries	10
2.2 Activities	11
2.3 Key initiative partners	15
2.4 Management structure	16
3. The strength of this initiative	19
3.1 Leveraging existing investments in maternal and child health	19
3.2 Supporting country-level impact through global coordination	19
3.3 Investing in surveillance, monitoring and evaluation	20
3.4 Implementing knowledge and best practices	21
References	23
Appendix 1: economic analysis and disability-adjusted life years calculations	26
Appendix 2: proposed budget for the initiative for the global elimination of mother-to-child transmission of syphilis	28
Appendix 3: list of tools available for country-level activities	29
Advocacy and programme tools	29
Clinical guidelines	29
Appendix 4: Battling Syphilis – a Team Approach (BASTA) participant affiliations	30



## Acknowledgements

The Department of Reproductive Health and Research (RHR) would like to thank all those who helped to elaborate this document and who provided critical review and input. This document was written by Sarah Hawkes (University College London) working with a primary development team including Nathalie Broutet (WHO), Mary Kamb (US Centers for Disease Control and Prevention, (CDC)), and Lori Newman (WHO). The economic and burden of disease estimates at the core of this document were contributed by Jim Kahn (University of California San Francisco), Gabriela Gomez (Amsterdam Institute for Global Health and Development), Aliya Jiwani (University of California San Francisco), and Harrell Chesson (CDC). WHO is also grateful for the input of the WHO regional focal points: Iyanthi Abeyewikreme, Monica Alonso, Hamida Khattabi, Lali Khotenashvili, Khadi Mbaye, Massimo Ghidinelli, and Teodora Wi.

This document was developed using a broad consultative process with external partners and the WHO secretariat, regional offices, and member states. From 2007 through 2009, a series of technical consultations were held to ensure that broad stakeholder input was obtained. The early and ongoing contributions of Deborah Atherly (PATH), Jeff Klausner (University of California San Francisco), Akjemal Magtymova (WHO), Jennifer Mark (CDC), Pablo Montoya (Health Alliance International), George Rutherford (University of California San Francisco), Bruce Shackman (Cornell University), Johannes Van Dam (Family Health International) and Ken Wind-Anderson (WHO), were very helpful in identifying document goals and approaches. Additionally, the contributions from consultation participants are gratefully acknowledged: Ian Askew (Population Council), Ron Ballard (CDC), Frida Behets (University of North Carolina), Stu Berman (CDC), Jan Bradley (EngenderHealth), Kent Buse (Overseas Development Institute), Flavia Bustreo (WHO), Xiang-Sheng Chen (China National STD Control Center), Wing-sie Cheng (UNICEF), Inam Chitsike (WHO), Simon Cousens (London School of Hygiene and Tropical Medicine), John Douglas (CDC), Peter Fajans (WHO), Vincent Fauveau (UNFPA), Dan Fitzgerald (Cornell University), Antonio Gerbase (WHO), Patricia Garcia (Universidad Peruana Cayetano Heredia), Sandy Garcia (Population Council), Stephen Gloyd (Health Alliance International), David Gold (Global Health Strategies), Patricia Gomez (JHPIEGO), Catherine Goodman (London School of Hygiene and Tropical Medicine), Cathy Grooms (CDC), Catherine Hankins (UNAIDS), Kara Hanson (London School of Hygiene and Tropical Medicine), Fraser Hore (Peacepath Consulting), Dale Huntington (WHO), Yojiro Ishit (Japan International Cooperation Agency), Monir Islam (WHO), Troy Jacobs (USAID), Wendy Johnson (Health Alliance International), Lily Kak (USAID), Eve Lackritz (CDC), Stefano Lazzari (Global Fund), Dede Leydorf (WHO), Craig Lissner (WHO), Ying-Ru Lo (WHO), Leah Lane Lowe (CDC Foundation), Chewe Luo (UNICEF), Sandra MacDonagh (United Kingdom Department for International Development), Tasneem Malik (CDC), Viviana Mangiaterra (WHO), Eva Margolies-Seiler (CDC), Jose Carlos Martines (WHO), Matthews Mathai (WHO), Bayalag Munkhuu (Mongolia State Research Centre), Olive Nakakeeto (independent consultant), Francis Ndowa (WHO), Kevin O'Reilly (WHO), Jos Perriens (WHO), Rosanna Peeling (London School of Hygiene and Tropical Medicine), Razia Pendse (WHO), Amy Pulver (CDC), Julie Rogers (CDC Foundation), Martha Roper (WHO), Caroline Ryan (U.S. Office of Global AIDS Coordination), Lale Say (WHO), Robert Scherpbier (WHO), George Schmid (WHO), Nathan Shaffer (CDC), Anuraj Shankar (WHO), Dorothy Shawn (FIGO), Elisa Sicuri (London School of Hygiene and Tropical Medicine), R.J. Simonds (CDC), Tin Tin Sint (WHO), Mike St. Louis (CDC), Bradley Stoner (Washington University St. Louis), Celine Taboy (CDC), Marleen Temmerman (University of Ghent), Feiko Ter Kuile (Liverpool School of Tropical Medicine), Ye Tun (CDC), and Peter Vickerman (London School of Hygiene and Tropical Medicine).

WHO acknowledges the financial support for this work from the Special Programme of Research, Development and Research Training in Human Reproduction (HRP), the U.S. Centers for Disease Control and Prevention, and UNFPA.

## Abbreviations and acronyms

ANC	antenatal care
BASTA	Battling Against Syphilis – a Team Approach
CDC	Centers for Disease Control and Prevention (USA)
DALY	disability-adjusted life year
DSTDP	Division of STD Prevention
MCA	WHO Department of Maternal, Child and Adolescent Health
MCH	maternal and child health
MDG	millennium development goal
MTCT	mother-to-child transmission (of syphilis and/or HIV)
NGO	nongovernmental organization
PAHO	Pan American Health Organization
PGT	programme guidance tool
PMTCT	prevention of mother-to-child transmission (of HIV)
RHR	WHO Department of Reproductive Health and Research
RPR	rapid plasma reagin
RTI	reproductive tract infection
STI	sexually transmitted infection
UN	United Nations
UNAIDS	Joint United Nations Programme on HIV/AIDS
UNFPA	United Nations Population Fund
UNICEF	United Nations Children’s Fund
USA	United States of America
VDRL	venereal disease research laboratory
WHO	World Health Organization

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_28354](https://www.yunbaogao.cn/report/index/report?reportId=5_28354)

